title: [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
abstract: Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil. It affects the skin of the palms and soles manifesting characteristic symptoms like erythema, inflammation, dysesthesia, pain, thickening, desquamation and cracking of the skin that may progress to cause wounds and ulceration, negatively influencing quality of life, psychological state and belief in recovery, which often result in the need of permanent or temporary interruption of the oncologic treatment and are potential sources of danger to the completion of the therapy. Adequate provision of the syndrome is of particular importance since a decline in adherence due to adverse events endangers precise maintenance of the self-sufficient oral treatment at home. Early recognition of symptoms, regular oncologic checkups and patient education on how to prevent or soothe the unpleasant skin toxicities could ensure a more successful treatment.
authors.affiliation: Intézeti Gyógyszertár, Országos Onkológiai Intézet, Budapest, Hungary. alexandra.bartal@gmail.com
authors.forename: Alexandra
authors.initials: A
authors.lastname: Bartal
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Mátrai
authors.forename: Attila
authors.initials: A
authors.lastname: Szûcs
authors.forename: Gabriella
authors.initials: G
authors.lastname: Liszkay
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000069287:Capecitabine; D003561:Cytarabine / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism; D000077143:Docetaxel; D004317:Doxorubicin / Q000009:adverse effects; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D017933:Peripheral Nervous System / Q000187:drug effects; D011788:Quality of Life; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects*; D013577:Syndrome; D043823:Taxoids / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D003561:Cytarabine; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D004317:Doxorubicin; D005472:Fluorouracil